# Regent Pacific Group

Regent Pacific Group is a Private Equity based in Central, Hong Kong.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Central, Hong Kong
- **Region:** Asia
- **Address:** Central, Hong Kong
- **Assets under management:** Undisclosed
- **Website:** endurancerp.com
- **LinkedIn:** https://www.linkedin.com/company/regent-pacific-management-corporation

## Regulatory record

- **Reports private funds:** No

## About

Regent Pacific Group is a Hong Kong based biopharmaceutical and investment company listed on the main board of the Hong Kong Stock Exchange (stock code: 575). It specialises in growth and value-led investments in the healthcare and late-stage life sciences spaces. The Group has two 100% owned proprietary products: Fortacin (Senstend in China), an approved treatment for premature ejaculation, and Deep Longevity, an AI digital health company focused on longevity through AI-powered ageing clocks.

## Sectors

- Healthcare Services
- Biotech & Life Sciences

## Questions

### How does Regent Pacific Group generate returns from its healthcare investments?

The firm acquires clinical-stage or approved assets — most notably through its subsidiary Plethora Solutions — and advances them to value-inflection milestones. Rather than build a commercial infrastructure, it licenses the assets to established pharmaceutical companies in exchange for upfront payments, regulatory milestones and sales royalties. Proceeds are then either reinvested into new acquisitions or returned to shareholders.

### Does Regent Pacific Group operate as a traditional private equity fund?

No. Regent Pacific is a publicly listed investment company on the Hong Kong Stock Exchange. It uses its own permanent balance sheet rather than raising third-party blind-pool capital with a fixed fund life. This gives it flexibility on holding periods but also means shareholders — not limited partners — bear the valuation and liquidity risks of its underlying holdings.

### Why is Regent Pacific structured as a Hong Kong-listed company rather than a private vehicle?

The public listing provides permanent capital without forced exit timelines and gives the firm an acquisition currency through its shares. It also creates a transparent mechanism for returning surplus capital to investors — through dividends or buybacks — after a monetization event. However, the structure requires public-market investors to underwrite illiquid biotech assets, a dynamic more common in European investment companies than in Asian markets.

## Related profiles

- [Regent](https://altss.com/profile/regent)
- [Regent's University London](https://altss.com/profile/regent-s-college)

---

Last updated: 2026-08-11T15:07:57.118Z

Canonical page: https://altss.com/profile/regent-pacific-group

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology